Brind.

Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.

Steady: 0 in the last 7 days Updated oct 13

The latest in this situation

  1. CMS began negotiating drug prices for AstraZeneca and Bristol-Myers Squibb drugs.
  2. Market performance diverges based on outlooks, and an agreement was reached to provide Eliquis free to the program.

How it started

1 report, 1 independent, last reported Aug 6. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.

Who's involved

What this event is mainly about
Hoffmann-La RocheNovo NordiskBristol-Myers Squibb

How it developed

Newest first. Tap a step to see who reported it.
  1. CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Sub-event
  2. Ongoing drug development updates across Parkinson's, ATTR amyloidosis, and Alzheimer's.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped